恒瑞医药多款药品被纳入2025年国家医保目录

Core Viewpoint - Heng Rui Medicine has successfully included several of its products in the National Medical Insurance Directory, which is expected to enhance sales and potentially improve the company's operational performance, although the exact impact remains uncertain [1][2]. Group 1: Inclusion in National Medical Insurance Directory - Heng Rui Medicine's products such as injection of Rukang Qutuzumab and others have been included in the National Medical Insurance Directory for 2025 [1]. - New indications for existing products like injection of Karilizumab and others have also been successfully added to the directory [1]. - Some products have retained their status in the directory, while others have had their indications adjusted to regular management [1]. Group 2: Financial Impact - The total sales for the aforementioned products are estimated to be approximately 8.66 billion yuan for 2024 and about 7.55 billion yuan for the first three quarters of 2025 [2]. - The implementation of the National Medical Insurance Directory will officially begin on January 1, 2026, with further details on payment standards and reimbursement to be announced by relevant government departments [2].